Partial Recanalization of a Large Vessel Acute Ischemic Stroke With Intravenous Tissue Plasminogen Activator, Followed by Systemic Anticoagulation, in the Setting of COVID-19-Induced Hypercoagulability: A Case Report.
Vincent A LaBarberaAidan AzherMahesh V JayaramanLinda C WendellDaniel C SacchettiBradford B ThompsonPublished in: The Neurohospitalist (2020)
We report on the use of systemic heparinization following thrombolysis with intravenous tissue plasminogen activator (t-PA) for acute ischemic large vessel stroke, in the setting of COVID-19-induced hypercoagulability, with partial recanalization of the internal carotid artery. Off-label systemic heparinization was used within 12 hours of t-PA administration, after extensive multidisciplinary collaboration and family discussion, given evidence of severe hypercoagulability. We conclude that thrombolysis should be considered for all eligible patients with suspected or confirmed COVID-19 and acute ischemic stroke, and systemic anticoagulation, although with inherent risks, may be a useful adjunct treatment modality in selected patients who have received intravenous thrombolysis.
Keyphrases
- acute ischemic stroke
- coronavirus disease
- drug induced
- sars cov
- internal carotid artery
- atrial fibrillation
- middle cerebral artery
- high dose
- high glucose
- end stage renal disease
- venous thromboembolism
- diabetic rats
- newly diagnosed
- ejection fraction
- pulmonary embolism
- respiratory syndrome coronavirus
- prognostic factors
- early onset
- peritoneal dialysis
- respiratory failure
- acute respiratory distress syndrome
- patient reported